bpc-157 and ghk-cu Glow Stack (BPC-157, TB-500 & GHK-Cu) bpc-157 lpt Understanding Peptides: BPC-157,

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

Solution: Use our peptide reconstitution calculator and dosage calculator

10.1002/jobm.202000575 J Basic Microbiol

Each draw contains 2 mg GHK-Cu and 0.4 mg each of BPC-157, TB-4, and KPV

If it is cloudy, contains particles that will not dissolve, or looks discolored, do not use it

The product uses a lab-tested, Arginine Salt version of BPC-157 designed for superior absorption, and it contains no synthetic fillers or artificial ingredients